Abstract
A series of doxorubicin-loaded polymer-caged nanobins (PCNDXR) were evaluated in vivo in a murine MDA-MB-231 xenograft model of triple-negative breast cancer. The cross-linked polymer cage in PCNDXR offers protection for the drug payload while serving as a pH-responsive trigger that enhances drug release in the acidic environments commonly seen in solid tumors and endosomes. Varying the degree of cross-linking in the polymer cage allows the surface potential of PCNDXR, and thus the in vivo circulation lifetime of the nanocarriers, to be tuned in a facile fashion. Given these design advantages, the present study provides the first in vivo evidence that PCNDXR can effectively inhibit tumor growth in a murine model of breast cancer. Importantly, PCNDXR was well-tolerated by mice, and drug encapsulation attenuated the toxicity of free doxorubicin. Taken together, this study demonstrates the potential utility of the PCN platform in cancer therapy.
| Original language | English |
|---|---|
| Pages (from-to) | 4971-4978 |
| Number of pages | 8 |
| Journal | ACS Nano |
| Volume | 4 |
| Issue number | 9 |
| DOIs | |
| State | Published - 28 Sep 2010 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- breast cancer
- in vivo drug delivery
- liposome
- pH-responsive release
- polymers
Fingerprint
Dive into the research topics of 'Biological evaluation of pH-responsive polymer-caged nanobins for breast cancer therapy'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver